Teriparatide acetate hydrate

Base Information

• Chemical Name: Teriparatide acetate hydrate
• CAS No.: 52232-67-4
• Molecular Formula: C181H291N55O51S2
• Molecular Weight: 4177.77
• Hs Code.: 2937190000
• European Community (EC) Number: 640-978-1
• NCI Thesaurus Code: C61966,C66588
• Pharos Ligand ID: UZ885S5YAP8C
• RXCUI: 32915,114260
• Wikipedia: Teriparatide
• Mol file: 52232-67-4.mol

Synonyms:Forteo;hPTH (1-34);Human Parathyroid Hormone (1-34);Parathar;Teriparatide;Teriparatide Acetate

Chemical Property of Teriparatide acetate hydrate

Chemical Property:

• Appearance/Colour: powder
• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: −20°C
• Solubility.: DMSO (Slightly), Water (Slightly)
• XLogP3: -18.7
• Hydrogen Bond Donor Count: 60
• Hydrogen Bond Acceptor Count: 62
• Rotatable Bond Count: 146
• Exact Mass: 4116.1342973
• Heavy Atom Count: 289
• Complexity: 9740

Purity/Quality:

99% ^*data from raw suppliers

ParathyroidHormoneFragment(1-34) ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Osteoporosis Agents
• Canonical SMILES: CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N
• Recent ClinicalTrials: Precision Medicine Approach for Osteoporosis - Follow Up Study
• Recent EU Clinical Trials: Treatment of adynamic bone disorder with parathyroid hormone in patients with chronic kidney disease
• Recent NIPH Clinical Trials: Japanese Osteoporosis Intervention Trial 06 (JOINT-06)
• Uses: A fragment of human parathyroid hormone (hPTH) peptide sequence containing the 34 N-terminal residues of hPTH. This fragment was also found to be an agonist at PTH1 and PTH2 receptors.
• Clinical Use: In 2002, the U.S. FDA approved teriparatide for the treatment of postmenopausal osteoporosis in patients who have a high risk of fracture as well as to increase bone mass in men with primary or hypogonadal osteoporosis who have a high risk of fracture. Teriparatide is recombinant human PTH 1-34, the biologically active portion of the endogenously produced preprohormone. Unlike the bisphosphonates, which are classified as bone restorative agents, teriparatide is the first approved bone-forming agent. Bone formation is possible because of the ability of this agent to increase the number of osteoblasts. Although teriparatide enhances the function of both osteoclasts and osteoblasts, the exposure incidence dictates its effect on the skeleton.